medigraphic.com

2023, Number 1

<< Back Next >>

Rev Hematol Mex 2023; 24 (1)

Costs of medical care of relapsed or refractory acute lymphoblastic leukemia in pediatric patients in health sector in Mexico

Hernández-Garduño AG, Carlos-Rivera F, Aubry MT, García-Fernández L, Camacho-Cordero LM, Fascinetto-Dorantes R, Meillon-García LA, Guzmán-Caniupan JA

Language: Spanish
References: 31
Page: 15-26
PDF size: 281.72 Kb.


ABSTRACT

Objective: To determine the costs of public institutional care in Mexican pediatric patients with relapsed or refractory acute lymphoblastic leukemia.
Materials and Methods: A pre-designed questionnaire was administered to ten institutional experts to ascertain the costs of routine medical care: medical consultations, laboratory and other tests, emergency care, general ward, and intensive care attention. The costs related to the IDA-FLAG treatment scheme (idarubicin, fludarabine, cytarabine and colony-stimulating factor), costs of adverse events (AEs) and costs related to end-of-life care.
Results: Pediatric patients with relapsed or refractory acute lymphoblastic leukemia non-responders compared to the responder group reported the following costs in Mexican pesos: routine costs $689,817 vs $172,088; cost of the IDA-FLAG scheme $176,938 vs $208,010; total annual expenditure of $380,099 and $941,516, respectively. In non-responders patients, the cost of terminal care was $74,760.
Conclusions: Total health care costs in pediatric patients with relapsed or refractory acute lymphoblastic leukemia increase three times more in non-responders compared to responders. This is the first study focused on determining the costs associated with the care of Mexican pediatric patients with relapsed or refractory acute lymphoblastic leukemia. Innovative therapies should be considered to treat acute lymphoblastic leukemia.


REFERENCES

  1. Lyengar V, Shimanovsky A. Leukemia. 2020 Aug 10. In:StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021.

  2. Childhood Acute Lymphoblastic Leukemia Treatment[PDQ(R)]: Health Professional Version, in PDQ CancerInformation Summaries. Updated on February 6, 2020:Bethesda (MD).

  3. Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblasticleukemia: an assessment of international incidence,survival, and disease burden. Cancer Causes Control 2015;26 (11): 1627-42. doi: 10.1007/s10552-015-0657-6.

  4. Pérez-Saldivar ML, Fajardo-Gutiérrez A, Bernáldez-Ríos R,Martínez-Avalos A, Medina-Sanson A, Espinosa-HernándezL, et al. Childhood acute leukemias are frequent in MexicoCity: descriptive epidemiology. BMC Cancer 2011; 11: 355.doi: 10.1186/1471-2407-11-355.

  5. Rivera GK, Ribeiro RC. Improving treatment of childrenwith acute lymphoblastic leukemia in developing countriesthrough technology sharing, collaboration and partnerships.Expert Rev Hematol 2014; 7 (5): 649-657. doi:10.1586/17474086.2014.949233.

  6. Abdelmabood S, Fouda AE, Boujettif F, Mansour A.Treatment outcomes of children with acute lymphoblasticleukemia in a middle-income developing country: highmortalities, early relapses, and poor survival. J Pediatr (RioJ) 2020; 96 (1): 108-116. doi: 10.1016/j.jped.2018.07.013.

  7. Jiménez-Hernández E, Jaimes-Reyes EZ, Arellano-GalindoJ, García-Jiménez X, Tiznado-García HM, Dueñas-GonzálezMT, et al. Survival of Mexican children with acute lymphoblasticleukaemia under treatment with the protocol fromthe Dana-Farber Cancer Institute 00-01. Biomed Res Int2015; 2015: 576950. doi: 10.1155/2015/576950.

  8. Jaime-Pérez, JC. El problema de la recaída en la leucemialinfoblástica aguda de la infancia. Rev Hematol Mex 2017;18 (1): 1-3.

  9. Contreras Yametti GP, Ostrow TH, Jasinski S, Raetz EA,Carroll WL, Evensen NA. Minimal residual disease in acutelymphoblastic leukemia: Current practice and future directions.Cancers (Basel) 2021; 13 (8): 1847. doi:10.3390/cancers13081847.

  10. Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A.Leukaemia and nutrition. I: Malnutrition is an adverseprognostic factor in the outcome of treatment of patientswith standard-risk acute lymphoblastic leukaemia.Leuk Res 1989; 13 (10): 899-906. doi: 10.1016/0145-2126(89)90043-x.

  11. Gómez-Almaguer D, Ruiz-Argüelles GJ, Ponce-de-LeónS. Nutritional status and socio-economic conditions asprognostic factors in the outcome of therapy in childhoodacute lymphoblastic leukemia. Int J Cancer Suppl 1998; 11:52-5. doi: 10.1002/(sici)1097-0215(1998)78:11+<52::aidijc15>3.0.co;2-3.

  12. Katz AJ, Chia VM, Schoonen WM, Kelsh MA. Acute lymphoblasticleukemia: an assessment of international incidence,survival, and disease burden. Cancer Causes Control 2015;26 (11): 1627-42. doi: 10.1007/s10552-015-0657-6.

  13. Liu Y, Chen J, Tang J, Ni S, Xue H, Pan C. Cost of childhoodacute lymphoblastic leukemia care in Shanghai, China.Pediatr Blood Cancer 2009; 53 (4): 557-62. doi: 10.1002/pbc.22127.

  14. Kaul S, Korgenski EK, Ying J, Ng CF, Smits-Seemann RR, NelsonRE, et al. A retrospective analysis of treatment-relatedhospitalization costs of pediatric, adolescent, and youngadult acute lymphoblastic leukemia. Cancer Med 2016; 5(2): 221-9. doi: 10.1002/cam4.583.

  15. Jaime-Pérez JC, Fernández LT, Jiménez-Castillo RA, Colunga-Pedraza JE, Padilla-Medina JR, Mancías-Guerra C, et al.Hospitalization rate and costs in acute lymphoblasticleukemia of childhood in a low-income group: Financialimpact in Northeast Mexico. Pediatr Blood Cancer 2017;64 (12). doi: 10.1002/pbc.26673.

  16. Enuvo GmbH, Seefeldstrasse 25, 8008 Zurich, Switzerland.https://www.onlineencuesta.com/.

  17. Protocolo de manejo para pacientes pediátricos con leucemiaaguda linfoblástica no tratados previamente. HospitalInfantil de México, Federico Gómez. http://www.himfg.edu.mx/descargas/documentos/planeacion/guiasclinicasHIM/LeuAguLinfoblastica.pdf.

  18. Instituto Mexicano del Seguro Social. Secretaría del HonorableConsejo Técnico. ACUERDO número ACDO.AS3.HCT.301120/310.P.DF dictado por el H. Consejo Técnico, ensesión ordinaria de 30 de noviembre de 2020, relativo a laAprobación de los Costos Unitarios por Nivel de AtenciónMédica actualizados al año 2021. Diario Oficial de la Federación28/12/2020. https://www.dof.gob.mx/nota_detalle.php?codigo=5608945&fecha=28/12/2020.

  19. Mustafa O, Abdalla K, AlAzmi AA, Elimam N, Abrar MB,Jastaniah W. FLAG/FLAG-IDA regimen for children withrelapsed/refractory acute leukemia in the era of targetednovel therapies. J Oncol Pharm Pract 2019; 25 (8): 1831-1838. doi: 10.1177/1078155218817816.

  20. Yılmaz Bengoa Ş, Ataseven E, Kızmazoğlu D, Demir YenigürbüzF, Erdem M, Ören H. FLAG Regimen with or withoutidarubicin in children with relapsed/refractory acuteleukemia: Experience from a Turkish pediatric hematologycenter. Turk J Haematol 2017; 34 (1): 46-51. doi: 10.4274/Tjh.2015.0411.

  21. Secretaría de Hacienda. Programa Anual de Adquisiciones,Arrendamientos y Servicios y Obra Pública (PAAASOP2021). https://procura-compranet.hacienda.gob.mx/paaasopdashboard/-.

  22. Instituto Nacional de Transparencia Acceso a la Informacióny Protección de Datos Personales (INAI). Solicitud deconsulta pública, No. 0064100241120-2. https://home.inai.org.mx/.

  23. Arroyave LMG, Ramírez NRF, Amador VL. Grupos Relacionadoscon el Diagnóstico: Producto Hospitalario GRD-IMSS2017. Instituto Mexicano del Seguro Social. http://www.imss.gob.mx/sites/all/statics/profesionalesSalud/economia/Libro-GRD2017.pdf.

  24. INEGI. Calculadora de Inflación. https://www.inegi.org.mx/app/indicesdeprecios/calculadorainflacion.aspx.

  25. Dirección General de Información en Salud (DGIS). Cubosdinámicos de Egresos Hospitalarios. Sector Salud (SSa,IMSS, IMSS-Oportunidades, ISSSTE, PEMEX, SEDENA,SEMAR, Otros). Instituciones Públicas morbilidad. 2008 a2017. http://www.dgis.salud.gob.mx/ contenidos/basesdedatos/std_egresoshospitalarios.html.

  26. Instituto Nacional de Estadística, Geografía e Informática(INEGI). Mortalidad, defunciones registradas, 2008-2017.https://www.inegi.org.mx/programas/mortalidad/.

  27. Sarkar RR, Gloude NJ, Schiff D, Murphy JD. Cost-effectivenessof chimeric antigen receptor T-cell therapy in pediatricrelapsed/refractory B-cell acute lymphoblastic leukemia.J Natl Cancer Inst 2019; 111 (7): 719-726. doi: 10.1093/jnci/djy193.

  28. Wakase S, Teshima T, Zhang J, Ma Q, Watanabe Y, YangH, et al. Cost-Effectiveness analysis of tisagenlecleucel forthe treatment of pediatric and young adult patients withrelapsed or refractory B cell acute lymphoblastic leukemiain Japan. Transplant Cell Ther 2021; 27 (3): 241.e1-241.e11.doi: 10.1016/j.jtct.2020.12.023.

  29. Walton M, Sharif S, Simmonds M, Claxton L, Hodgson R.Tisagenlecleucel for the treatment of relapsed or refractoryB-cell acute lymphoblastic leukaemia in people aged up to25 years: An evidence review group perspective of a NICEsingle technology appraisal. Pharmacoeconomics 2019;37 (10): 1209-1217. doi: 10.1007/s40273-019-00799-0.

  30. Furzer J, Gupta S, Nathan PC, Schechter T, Pole JD, KruegerJ, et al. Cost-effectiveness of tisagenlecleucel vs standardcare in high-risk relapsed pediatric acute lymphoblasticleukemia in Canada. JAMA Oncol 2020; 6 (3): 393-401. doi:10.1001/jamaoncol.2019.5909.

  31. Bhojwani D, Pui CH. Relapsed childhood acute lymphoblasticleukaemia. Lancet Oncol 2013; 14 (6): e205-17. doi:10.1016/S1470-2045(12)70580-6.




2020     |     www.medigraphic.com